Immuneering Corporation announced on July 9, 2025, that the United States Patent and Trademark Office (USPTO) granted the company a composition of matter patent for atebimetinib (IMM-1-104). This patent, U.S. Patent No. 12,351,566, titled: “MEK Inhibitors and Therapeutic Uses Thereof”, includes claims to atebimetinib’s composition of matter.
The newly issued patent is expected to provide exclusivity into August 2042, including a patent term adjustment, with the potential for further patent term extension to recover a portion of the time required for regulatory approval. Additional patent applications for methods of use and pharmaceutical compositions are pending, with expiration expected into 2044.
This robust intellectual property protection is crucial for safeguarding Immuneering's competitive position and maximizing the commercial value of its lead asset, which recently demonstrated a 94% probability of surviving 6 months in first-line pancreatic cancer patients in its Phase 2a study, compared to 67% for the standard of care chemotherapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.